Korean J Med.
2024 Apr;99(2):78-83. 10.3904/kjm.2024.99.2.78.
Recent Progression of Incretin-Based Obesity Treatment
- Affiliations
-
- 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea
- KMID: 2554307
- DOI: http://doi.org/10.3904/kjm.2024.99.2.78
Abstract
- Incretin-based obesity treatments are making remarkable progress, marking a new era in the field of obesity pharmacotherapy. These treatments not only meet the long-standing demands for safety and sustainability in obesity medications but also go beyond, significantly improving complications associated with obesity, such as cardiovascular diseases. This review explores the advancement in obesity treatments through the latest research findings on semaglutide and tirzepatide, two incretin-based obesity treatments currently receiving considerable attention.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
- Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
- In Vivo Models for Incretin Research: From the Intestine to the Whole Body
- New Therapeutics for Diabetes Using Incretin Hormone
- An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
